Having successfully navigated a two-day, virtual advisory committee review of cancer drug pediatric development plans, the US Food and Drug Administration is ready to embark on its first application-specific virtual meeting, with the oncology panel once again serving as a test bed.
Going Virtual: GSK’s Multiple Myeloma Drug Belantamab Tapped For US FDA Online AdComm In July
Announcement of the 14 July Oncologic Drugs Advisory Committee meeting follows a successful, two-day trial run of the virtual format by the oncology pediatric subcommittee that featured a mix of prerecorded and live sponsor presentations and strict adherence to a call/response approach to ensure orderly conduct.
